Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 250K | 0 | 12K | 238K | 0 | 0 | 0 | 50K | 580K | 6K |
Operating revenue | --250K | --0 | --12K | --238K | --0 | --0 | --0 | --50K | --580K | --6K |
Cost of revenue | 31K | 0 | 1K | 30K | 0 | 0 | 0 | 0 | 275K | 7K |
Gross profit | 219K | 0 | 11K | 208K | 0 | 0 | 0 | 50K | 305K | -1K |
Operating expense | 181.54M | 24.70%50.44M | -36.15%47.26M | 45.06M | 126.95%38.78M | 186.38%40.45M | 499.45%74.01M | 4,738.57%17.09M | 50.33M | 5,292.10%14.12M |
Selling and administrative expenses | --34.13M | -3.62%8.83M | -72.10%9.48M | --8.66M | 19.08%7.16M | 100.37%9.16M | 697.89%33.97M | 1,602.52%6.01M | --17.99M | 1,645.44%4.57M |
-Selling and marketing expense | --3.87M | 71.16%1.21M | -5.06%1.03M | --876K | 120.88%751K | 137.04%704K | 699.26%1.09M | --340K | --801K | --297K |
-General and administrative expense | --30.27M | -9.85%7.62M | -74.31%8.45M | --7.79M | 12.97%6.41M | 97.82%8.46M | 697.84%32.89M | 1,506.25%5.67M | --17.19M | 1,532.06%4.28M |
Research and development costs | --65.79M | 80.10%20.28M | 16.42%17.57M | --16.35M | 49.35%11.57M | 83.38%11.26M | 216.80%15.09M | --7.74M | --18.95M | --6.14M |
Depreciation amortization depletion | --81.62M | 6.52%21.33M | -18.98%20.21M | --20.05M | 501.95%20.06M | 486.84%20.03M | 650.23%24.95M | --3.33M | --13.39M | --3.41M |
-Depreciation and amortization | --81.62M | 6.52%21.33M | -18.98%20.21M | --20.05M | 501.95%20.06M | 486.84%20.03M | 650.23%24.95M | --3.33M | --13.39M | --3.41M |
Operating profit | -181.32M | -24.70%-50.44M | 36.16%-47.25M | -44.85M | -127.61%-38.78M | -186.36%-40.45M | -503.95%-74.01M | -4,724.41%-17.04M | -50.03M | -5,292.48%-14.13M |
Net non-operating interest income expense | 31.39M | -23.01%6.68M | -26.00%7.99M | 9.03M | 25,733.33%7.69M | 361.16%8.67M | 10.8M | -198.44%-30K | -4.79M | -38,281.19%-3.32M |
Total other finance cost | ---31.39M | 23.01%-6.68M | 26.00%-7.99M | ---9.03M | -25,733.33%-7.69M | -361.16%-8.67M | ---10.8M | --30K | --4.79M | --3.32M |
Other net income (expense) | -25.29M | -162.48%-54.66M | 119.78%27.69M | 16.26M | -728,950.00%-14.58M | 2,916,033.33%87.48M | -411,935.29%-140.02M | -99.99%2K | 38K | 100.06%3K |
Gain on sale of security | ---25.66M | -162.88%-55.02M | 119.77%27.69M | --16.25M | ---- | --87.49M | ---140.03M | ---- | ---- | ---- |
Special income (charges) | ---- | ---- | ---- | ---- | ---14.58M | ---- | ---- | --0 | ---- | ---- |
-Less:Restructuring and merger&acquisition | ---- | ---- | ---- | ---- | --14.58M | ---- | ---- | --0 | ---- | ---- |
Other non- operating income (expenses) | --364K | 6,000.00%354K | -40.00%3K | --6K | ---- | -300.00%-6K | -85.29%5K | --2K | --38K | --3K |
Income before tax | -175.22M | -276.68%-98.43M | 94.31%-11.56M | -19.57M | -167.59%-45.67M | 419.38%55.71M | -1,563.11%-203.23M | -197.12%-17.07M | -54.78M | -213.30%-17.44M |
Income tax | -10.58M | 111.08%557K | -596.92%-4.75M | -2.35M | -4.04M | -5.03M | -681K | 0 | 0 | 0 |
Net income | -164.64M | -262.97%-98.98M | 96.64%-6.81M | -17.22M | -143.93%-41.63M | 448.19%60.74M | -1,557.54%-202.55M | -197.12%-17.07M | -54.78M | -213.30%-17.44M |
Net income continuous Operations | ---164.64M | -262.97%-98.98M | 96.64%-6.81M | ---17.22M | -143.93%-41.63M | 448.19%60.74M | -1,557.54%-202.55M | -197.12%-17.07M | ---54.78M | -213.30%-17.44M |
Minority interest income | -115.45M | -269.15%-64.66M | 94.43%-7.63M | -12.95M | -30.21M | 38.23M | -136.99M | 0 | 0 | 0 |
Net income attributable to the parent company | -49.19M | -252.48%-34.32M | 101.25%818K | -4.27M | 33.08%-11.42M | 229.04%22.51M | -436.53%-65.56M | -201.01%-17.07M | -54.78M | -225.83%-17.44M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -49.19M | -252.48%-34.32M | 101.25%818K | -4.27M | 33.08%-11.42M | 229.04%22.51M | -436.53%-65.56M | -201.01%-17.07M | -54.78M | -225.83%-17.44M |
Basic earnings per share | -0.67 | -235.29%-0.46 | 101.04%0.01 | -0.06 | 96.48%-0.16 | 184.06%0.34 | 91.02%-0.96 | -1,266.67%-4.55 | -14.79 | -237.06%-0.4045 |
Diluted earnings per share | -0.67 | -235.29%-0.46 | 101.04%0.01 | -0.06 | 96.48%-0.16 | 184.06%0.34 | 91.02%-0.96 | -1,266.67%-4.55 | -14.7937 | -237.06%-0.4045 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |